These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen. Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990 [TBL] [Abstract][Full Text] [Related]
3. Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. Halberstadt AL; Luethi D; Hoener MC; Trachsel D; Brandt SD; Liechti ME Psychopharmacology (Berl); 2023 Jan; 240(1):115-126. PubMed ID: 36477925 [TBL] [Abstract][Full Text] [Related]
4. G Liu X; Zhu H; Gao H; Tian X; Tan B; Su R Biochem Biophys Res Commun; 2022 Apr; 598():20-25. PubMed ID: 35149433 [TBL] [Abstract][Full Text] [Related]
5. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Canal CE; Booth RG; Morgan D Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901 [TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT Pottie E; Poulie CBM; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Kristensen JL; Stove CP ACS Chem Neurosci; 2023 Aug; 14(15):2727-2742. PubMed ID: 37474114 [TBL] [Abstract][Full Text] [Related]
7. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097 [TBL] [Abstract][Full Text] [Related]
9. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152 [TBL] [Abstract][Full Text] [Related]
10. The selective 5-HT Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690 [TBL] [Abstract][Full Text] [Related]
11. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043 [TBL] [Abstract][Full Text] [Related]
12. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. Canal CE; Cordova-Sintjago T; Liu Y; Kim MS; Morgan D; Booth RG J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681 [TBL] [Abstract][Full Text] [Related]
13. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT Di Giovanni G; De Deurwaerdère P Neuropharmacology; 2018 Nov; 142():20-29. PubMed ID: 28987938 [TBL] [Abstract][Full Text] [Related]
14. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Smith RL; Canton H; Barrett RJ; Sanders-Bush E Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567 [TBL] [Abstract][Full Text] [Related]
15. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361 [TBL] [Abstract][Full Text] [Related]
16. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice. Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. Halberstadt AL; Chatha M; Chapman SJ; Brandt SD J Psychopharmacol; 2019 Mar; 33(3):406-414. PubMed ID: 30789291 [TBL] [Abstract][Full Text] [Related]
20. A new class of 5-HT Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]